DaVita Inc
Research DaVita Inc (DVA) on Bullrun: valuation model: 1.9% undervalued, market cap USD 10.44B, P/E 15.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDVA
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Care Facilities
- CurrencyUSD
- Valuation signal1.9% undervalued
- Market capUSD 10.44B
- P/E15.0
- Financial periodQ2 2026
- RevenueUSD 3.55B
- Net incomeUSD 265.40M
- Free cash flowUSD 320.25M
- Gross margin32.7%
Valuation Snapshot
Bullrun's latest valuation model marks DaVita Inc as 1.9% undervalued; latest market cap is USD 10.44B; P/E is 15.0.
Peer valuation comparison
Latest P/E is 14.99x versus a Healthcare sector median of 24.46x (38.7% below).
Latest P/E is 14.99x versus a United States median of 24.87x (39.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 13.64B | USD 1.08B | USD 1.31B | 32.2% | 9.84 | USD 676.44M | USD 12.87B | -USD 651.08M |
| FY2024 | USD 12.82B | USD 1.25B | USD 1.47B | 32.9% | 10.73 | USD 794.93M | USD 12.07B | USD 121.12M |
| FY2023 | USD 12.14B | USD 956.98M | USD 1.49B | n/a | 7.42 | USD 380.06M | USD 11.12B | USD 1.06B |
| FY2022 | USD 11.61B | USD 781.64M | USD 961.14M | n/a | 5.85 | USD 244.09M | USD 12.27B | USD 712.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.44B | 15.0 | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.79B | 11.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 12.04B | 13.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 9.57B | 16.4 | n/a | n/a |
| 2022 | 2022-12-30 | USD 6.73B | 10.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 11.07B | 12.8 | n/a | n/a |
About DaVita Inc
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is DaVita Inc overvalued or undervalued?
Bullrun's valuation model currently marks DaVita Inc as 1.9% undervalued.
What is DaVita Inc's market cap?
DaVita Inc's market capitalization is USD 10.44B.
What is DaVita Inc's P/E ratio?
DaVita Inc's price-to-earnings (P/E) ratio is 15.0.
What does DaVita Inc do?
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.